NeuroBo Pharmaceuticals, Inc.


4.08 (USD) • At close July 24, 2024
Bedrijfsnaam NeuroBo Pharmaceuticals, Inc.
Symbool NRBO
Munteenheid USD
Prijs 4.085
Beurswaarde 33,582,948
Dividendpercentage 0%
52-weken bereik 2.9 - 6.75
Industrie Biotechnology
Sector Healthcare
CEO Mr. Hyung-Heon Kim

An error occurred while fetching data.

Over NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat

Vergelijkbare Aandelen

Cyclacel Pharmaceuticals, Inc. logo

Cyclacel Pharmaceuticals, Inc.


11.81 USD

Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc.


0.408 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)